Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers

V. Klementa, N. Petejova, P. Horak, E. Kurasova, J. Zadrazil

. 2025 ; 169 (1) : 1-8. [pub] 20241011

Language English Country Czech Republic

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25008978

Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008978
003      
CZ-PrNML
005      
20250521143021.0
007      
ta
008      
250411s2025 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2024.031 $2 doi
035    __
$a (PubMed)39403944
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Klementa, Viktor $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic $7 xx0275433
245    10
$a Acute kidney injury due to gentamicin nephrotoxicity and specific miRNAs as biomarkers / $c V. Klementa, N. Petejova, P. Horak, E. Kurasova, J. Zadrazil
520    9_
$a Acute kidney injury (AKI) due to gentamicin nephrotoxicity is a significant concern in clinical medicine, particularly in patients receiving prolonged or high-dose gentamicin therapy. Gentamicin is an aminoglycoside antibiotic frequently used in the treatment of a range of bacterial infections. However, its use is associated with nephrotoxicity which can manifest as AKI. Due to this, it is crucial to diagnose promptly and manage treatment effectively. Ongoing studies are therefore focusing on non-protein-coding RNAs as potential biomarkers for AKI. Numerous microRNAs (miRNAs) have been implicated in gentamicin-induced nephrotoxicity and AKI. They participate in pathways associated with inflammation, cell death, and oxidative stress and each of these factors play critical roles in the development of gentamicin-induced kidney injury. Research studies have demonstrated changes in the expression levels of these miRNAs in response to gentamicin exposure both in vitro and in in vivo models, as well as in human clinical trials involving patients receiving gentamicin therapy. The dysregulation of these miRNAs correlates with the severity of kidney injury and may serve as sensitive biomarkers for early detection and monitoring of AKI induced by gentamicin.
650    12
$a gentamiciny $x škodlivé účinky $7 D005839
650    12
$a akutní poškození ledvin $x chemicky indukované $x diagnóza $7 D058186
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $7 D035683
650    12
$a biologické markery $7 D015415
650    12
$a antibakteriální látky $x škodlivé účinky $7 D000900
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Petejová, Naděžda $u Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $7 xx0143726
700    1_
$a Horák, Pavel, $d 1966- $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic $7 xx0032850
700    1_
$a Kurašová, Ester $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic $7 xx0280026
700    1_
$a Zadražil, Josef, $d 1954- $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic $7 xx0074493
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 169, č. 1 (2025), s. 1-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39403944 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20250411 $b ABA008
991    __
$a 20250521143018 $b ABA008
999    __
$a ok $b bmc $g 2324854 $s 1246056
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 169 $c 1 $d 1-8 $e 20241011 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK124 $a Pubmed-20250411

Find record

Citation metrics

Archiving options